{
    "clinical_study": {
        "@rank": "35345", 
        "arm_group": [
            {
                "arm_group_label": "CHF1535 NEXThaler 100/6, 1 puff", 
                "arm_group_type": "Active Comparator", 
                "description": "Beclometasone Dipropionate 100 \u00b5g + Formoterol Fumarate 6 \u00b5g"
            }, 
            {
                "arm_group_label": "CHF1535 NEXThaler 100/6 \u00b5g, 4 puffs", 
                "arm_group_type": "Active Comparator", 
                "description": "Beclometasone Dipropionate 400 \u00b5g + Formoterol Fumarate 24 \u00b5g"
            }, 
            {
                "arm_group_label": "CHF1535 NEXThaler 200/6 \u00b5g, 1 puff", 
                "arm_group_type": "Experimental", 
                "description": "Beclometasone Dipropionate 200 \u00b5g + Formoterol Fumarate 6 \u00b5g"
            }, 
            {
                "arm_group_label": "CHF1535 NEXThaler 200/6 \u00b5g, 4 puffs", 
                "arm_group_type": "Experimental", 
                "description": "Beclometasone Dipropionate 800 \u00b5g + Formoterol Fumarate 24 \u00b5g"
            }, 
            {
                "arm_group_label": "Placebo NEXThaler", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to demonstrate the non-inferiority in terms of acute bronchodilator\n      effect between a single dose of CHF 1535 NEXThaler 200/6 \u00b5g and a single dose of CHF 1535\n      NEXThaler 100/6 \u00b5g at two dose levels in partially controlled and uncontrolled asthmatic\n      patients."
        }, 
        "brief_title": "A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient's written informed consent obtained prior to any study-related procedures.\n\n          -  Male or female aged between 18 and 65 years inclusive;\n\n          -  Evidence for \"partially controlled\" or \"uncontrolled\" asthma;\n\n          -  Medium daily dose of previous inhaled corticosteroids (ICS) treatment;\n\n          -  FEV1 between 60% and 85% of the predicted normal values;\n\n          -  A documented positive response to the reversibility test;\n\n          -  Non-smokers or ex-smokers;\n\n          -  A cooperative attitude and ability to be trained in the proper use of a DPI.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women and all women physiologically capable of becoming\n             pregnant not willing to use at least one acceptable method of contraception.\n\n          -  Significant seasonal variation in asthma occurring or expected to occur during study\n             participation;\n\n          -  History of near fatal asthma, brittle asthma, accident and Emergency treatment or\n             hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before\n             screening;\n\n          -  Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks\n             preceding the screening;\n\n          -  Diagnosis of Chronic Obstructive Pulmonary Disease;\n\n          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency;\n\n          -  Diagnosis of restrictive lung disease;\n\n          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks;\n\n          -  Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled\n             corticosteroids;\n\n          -  Allergy, sensitivity or intolerance to study drugs or excipients;\n\n          -  Patients who received any investigational drug within the last 8 weeks before the\n             screening;\n\n          -  Patients taking any of the non-permitted concomitant medication;\n\n          -  Subjects unlikely to comply with the study protocol;\n\n          -  Any clinically relevant abnormal value or physical finding at screening;\n\n          -  Significant medical history;\n\n          -  Abnormal and clinically significant 12-lead electrocardiogram;\n\n          -  Patients with low compliance of QVAR intake."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148120", 
            "org_study_id": "CCD-01535BA1-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CHF1535 NEXThaler 100/6, 1 puff", 
                    "CHF1535 NEXThaler 100/6 \u00b5g, 4 puffs"
                ], 
                "intervention_name": "Beclometasone Dipropionate 100 \u00b5g + Formoterol Fumarate 6 \u00b5g", 
                "intervention_type": "Drug", 
                "other_name": "Foster NEXThaler"
            }, 
            {
                "arm_group_label": [
                    "CHF1535 NEXThaler 200/6 \u00b5g, 1 puff", 
                    "CHF1535 NEXThaler 200/6 \u00b5g, 4 puffs"
                ], 
                "intervention_name": "Beclometasone Dipropionate 200 \u00b5g + Formoterol Fumarate 6 \u00b5g", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo NEXThaler", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol", 
                "Bronchodilator Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W1G 8HU"
                    }, 
                    "name": "Respiratory Clinical Trials, Hearth Lung Centre"
                }, 
                "investigator": {
                    "last_name": "Brian Leaker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW10 7EW"
                    }, 
                    "name": "Hammersmith Medicines Research"
                }, 
                "investigator": {
                    "last_name": "Adeep Puri, MPhil", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9QZ"
                    }, 
                    "name": "Medicines Evaluation Unit"
                }, 
                "investigator": {
                    "last_name": "Dave Singh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase II, Multicentre, Double-blind, Randomised, 5-way Crossover Study to Test the Non-inferiority of the Acute Bronchodilator Effect of CHF 1535 200/6 \u00b5g NEXThaler Versus CHF 1535 100/6 \u00b5g NEXThaler in Partially Controlled and Uncontrolled Adult Asthmatic Patients.", 
        "overall_contact": {
            "email": "s.collarini@chiesi.com", 
            "last_name": "Sara Collarini, MSc", 
            "phone": "+390521279948"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "FEV1= Forced expiratory volume in the first second of expiration", 
            "measure": "FEV1 Area under the curve", 
            "safety_issue": "No", 
            "time_frame": "until 12 h post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum FEV1 value", 
                "measure": "FEV1 peak", 
                "safety_issue": "No", 
                "time_frame": "until 12 h post dose"
            }, 
            {
                "description": "FVC = Forced Vital Capacity", 
                "measure": "FVC area under the curve", 
                "safety_issue": "No", 
                "time_frame": "until 12 h post dose"
            }, 
            {
                "description": "Maximum FVC", 
                "measure": "FVC peak", 
                "safety_issue": "No", 
                "time_frame": "until 12 h post dose"
            }, 
            {
                "description": "from the signature of the informed consent until the end of the study, the total duration depends on the duration of the run-in and wash-out periods.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "over a period of 5 to 14 weeks"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}